Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-mannuronic acid
- Development stage
- Phase 2
- Modality
- Small Molecules
- Administration
- Oral, Topical, Intravenous, Subcutaneous, Intramuscular
01
Overview
D-mannuronic acid is a uronic acid monosaccharide and a key monomeric unit of alginate, a natural polysaccharide found in brown algae. It is commonly used in its sodium salt form for biomedical applications, particularly as a component in the production of alginate hydrogels for drug delivery systems. These hydrogels are valued for their ability to encapsulate drugs and enable controlled release, making them useful in research on cancer, bacterial infections, and cardiovascular diseases[4]. β-D-Mannuronic Acid (sometimes referred to as M2000) has also been studied as an experimental non-steroidal anti-inflammatory drug (NSAID) with immunosuppressive properties and potential antidiabetic, cardioprotective, and anti-tumoral effects[7][5]. The mechanism of action involves modulation of immune responses; however, specific molecular targets are not fully established.
- Other names
- D-mannuronateManA
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)IRAK1 (Interleukin-1 receptor-associated kinase 1)MYD88 (Myeloid differentiation primary response protein MyD88)NF-κBTLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)TRAF6PGHS-1 (Prostaglandin G/H Synthase 1)GATA3 (GATA Binding Protein 3)IL-17A (Interleukin-17A)IL-4 (Interleukin 4)IL-6 (Interleukin 6)MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)RORC (Retinoic acid receptor-related orphan receptor gamma)TIMP1 (Metalloproteinase inhibitor 1)TIMP2TNFA (Tumor necrosis factor alpha (soluble))miR-146a (microRNA-146a)
Beyond the preview
Go deeper on D-mannuronic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D-mannuronic acid.